Implementation readiness of artificial intelligence in in vitro fertilization: a multi-framework appraisal with special reference to advanced reproductive age patients

Even when evidence and economics favor adoption, AI systems introduce failure modes distinct from conventional medical devices and require dedicated mitigation. Unlike obvious equipment failures, AI models fail silently—producing confident but incorrect outputs that clinicians may act upon unaware ( 31 ). These failures include: Models trained on historical data degrade when patient populations, protocols, or equipment change. An embryo scoring model trained on patients aged 28–38 may underperform for those >40 or with endometriosis. Mitigation: continuous performance monitoring with automated alerts; periodic retraining; reporting of model version and training demographics ( 3 , 31 , 38 ). Cloud-dependent AI systems are vulnerable to outages. In time-sensitive IVF decisions (trigger timing, transfer scheduling), outages force reversion to manual protocols. Mitigation: documented manual fallback protocols for AI-integrated workflows; on-premise deployment with cloud sync; contractual service-level agreement (SLA) ( 32 , 78 ). Deep learning models can be sensitive to image artifacts (bubbles, debris, optical aberrations) that do not affect human assessment, and encounter edge cases like arrested development, mosaic embryos, and culture artifacts. Mitigation: adversarial testing during validation; human oversight for edge cases; transparent confidence intervals on all AI outputs ( 3 , 23 , 37 ). When AI contributes to a harmful clinical decision, responsibility among clinician, institution, and vendor remains legally unresolved. The EU AI Act classifies certain AI medical devices as high-risk, but liability remains ambiguous. Under the learned intermediary doctrine—which holds the treating clinician, not the manufacturer, primarily liable—the hospital currently bears malpractice exposure when AI informs embryo selection or transfer decisions. Until insurers establish explicit underwriting frameworks for AI-augmented ART, institutional risk committees will likely restrict these tools to observational or adjunctive roles ( 78 ). Each of these failure modes intersects with one or more of the implementation prerequisites considered in the next chapter.

The Methodology section above establishes the analytical framework. This chapter translates that scaffolding into a deployable AI toolkit organized by clinical resource tier ( Table 3 ). Subsequent chapters provide the technology-by-technology evidence, critical appraisal, implementation prerequisites, and ARA-specific synthesis that support the suggestions made here. A deployable AI toolkit for the 2026 IVF clinic. Six AI tools stratified by deployment tier: Tier 1 = software licensing only (no capital hardware; includes FDA-cleared T4 CycleClarity); Tier 2 = time-lapse incubation infrastructure required; Tier 3 = research capacity required. Tier (infrastructure burden) and Wave (timeline to widespread adoption) are independent axes: T4 has FDA-cleared platforms (Tier 1 infrastructure) but its evidence maturity and validation status place broad deployment in Wave 2 (5–10 years). Columns: product name(s), regulatory status, evidence level (OCEBM), and ARA relevance. All AI tools should be implemented as adjuncts to, not replacements for, clinical judgment. The Tier 1 toolkit requires only software licensing, electronic health record (EHR) integration, and staff training. First, RFID-based electronic witnessing (T3) systems (e.g., RI Witness (CooperSurgical), Vitrolife eWitness, and Gidget (Hamilton Thorne)) are all commercially deployed ( 33 ). For example, RI Witness uses passive RFID tags and workstation readers to provide continuous automatic monitoring, and the per-cycle licensing makes it accessible at any volume ( 33 ). Second, AI outcome prediction (T1) systems such as the Univfy PreIVF ML models has been validated in a 2025 study demonstrating significantly improved discriminatory performance over national registry age-based prediction ( 22 , 34 ). This model could inform counseling on expectations, multi-cycle planning, and the autologous/donor decision. Third, AI stimulation dosing (T2) system is available as a module within the CHLOE platform (Fairtility) or built as a center-specific starting-dose ML model from existing electronic medical record (EMR) data ( 23 , 32 ). Clinics with time-lapse infrastructure can immediately add the AI embryo assessment tool (T6). CHLOE Blast (Fairtility; FDA 510(k) cleared September 2025; CE marked; building on the algorithm originally described by 35 ) is the first FDA-cleared ML clinical decision support tool for embryo assessment. Vitrolife offers iDAScore v2 ( 36 ) and KIDScore D5 v3 (both CE marked), however, the 14-center iDAScore RCT failed to demonstrate non-inferiority for clinical pregnancy rate (risk difference −1.7%, 95% CI −7.7 to 4.3; 27 ). These tools should remain adjuncts to embryologist assessment until head-to-head live birth endpoint data are available (see the Evidence Quality section for critical appraisal of divergent RCT evidence). High-volume centers (>1,000 cycles/year) with established data infrastructure and research programs can extend the toolkit to include AI-assisted endometrial receptivity assessment (T7). While no AI endometrial tool carries FDA or CE-mark regulatory clearance specifically for endometrial receptivity assessment as of April 2026, validated AI models integrating endometrial pattern recognition with embryo quality scoring have been demonstrated in published research and are entering the translational pipeline ( 37 ). These centers can also participate in multicenter validation trials for T5b (AI sperm selection, exemplified by the Carrión-Sisternas et al. ( 26 ) platform), contributing to the evidence base. Tier 3 clinics should additionally invest in the EHR and laboratory information management system (LIMS) infrastructure to enable multi-modal AI fusion ( 3 , 38 ). The infrastructure investment required at this tier will require one-time setup cost plus ongoing annual maintenance. For IVF physicians managing predominantly ARA patients (≥40 years), the deployment cascade in 2026 could combine Tier 1 tools with T6 adjunctive embryo assessment: T1 prognosis counseling at the first visit, T2 stimulation dosing optimization, T6 embryo prioritization in time-lapse-equipped centers, and universal T3 electronic witnessing (with amplified medicolegal importance in ARA cases where each embryo is irreplaceable). The ARA Patient: Integrated Clinical Synthesis chapter walks this cascade through a representative composite ARA case (Mrs. K) and presents the underlying ARA-AI amplification mechanism. Before committing to any AI integration contract, clinics should address three foundational questions concerning data ownership and portability, algorithmic drift monitoring obligations, and uptime service-level agreements with manual fallback protocols. These questions, and their analytical rationale, are detailed in the Procurement section.

The preceding chapters have evaluated nine AI technologies as discrete entities. This chapter integrates that analysis to address a common clinical question: how does the AI-integrated IVF clinic actually function for the patient population in whom AI delivers the greatest value? This review suggests that patients of advanced reproductive age (≥40 years) represent that particular population. AI amplification for ARA patients could be realized across multiple technologies: discriminatory advantage rises with maternal age in T6 embryo selection, individualized stimulation calibration matters more in diminished ovarian reserve in T2, and prognosis miscalibration carries higher stakes when treatment windows are short in T1. This means that a coherent ARA-specific clinical setting serves both as a stress test for the toolkit and as a practical guide for the IVF physicians for whom these patients represent a substantial fraction of their caseload. Mrs. K is a composite figure, drawn from the clinical features representative of advanced reproductive age patients with diminished ovarian reserve ( Figure 3 ). The clinical scenario that follows describes care that could be delivered today, in 2026, for Mrs. K using only the Wave 1 and Wave 2 technologies in adequately resourced centers. T1 outcome prediction, T2 stimulation dosing, and T3 RFID quality tracking are deployable now, whereas the T6 AI embryo assessment is available adjunctively in time-lapse-equipped centers. While the T8 miscarriage risk prediction trajectory is beyond 2031 for routine deployment, it could inform the ARA-specific research agenda now. Each decision point in her care outlined below maps to a specific AI technology, a specific evidence finding, and a specific deployment status in 2026. Clinical vignette — Mrs. K: composite advanced reproductive age (ARA) patient’s journey through the AI-integrated IVF protocol. Patient profile: age 41, AMH 0.6 ng/mL, AFC 6, FSH 12.4 IU/L, 22 months unsuccessful conception. Seven discrete technology touchpoints, plus a cross-cutting T3 RFID quality-tracking banner, are traced through four clinical phases: T1 (initial outcome prediction and revised counseling), T2 (stimulation dosing), T6 (embryo assessment via KIDScore; AUC 0.679 at age 41–42, 1 ), T6 (ploidy prediction using the ERICA algorithm, 77 — distinct from the T8 ERICA miscarriage application), T8 (miscarriage risk scoring; AUC ~0.70, not yet sufficient for transfer withholding), T1 (revised counseling from actual cycle response), and T1+T6 (cascade synthesis for autologous-versus-donor decision support). A horizontal T3 banner spanning all phases represents RFID electronic witnessing, which is active throughout the laboratory workflow and carries amplified medicolegal importance in ARA cases where each embryo is irreplaceable. Detail annotation cards below each touchpoint show clinical parameters and evidence metrics. Wave color coding: blue = Wave 1 (≤5 yr, Adopt Now); amber = Wave 2 (5–10 yr, Pilot); red = Wave 3 (>10 yr, Future). ARA-AI amplification T1, T2, and T6 each deliver proportionally greater discriminatory value at advanced reproductive age than in younger patient cohorts. Mrs. K is 41 years old, presenting after 22 months of unsuccessful conception. Her AMH is 0.6 ng/mL; antral follicle count is 6; day-3 FSH is 12.4 IU/L. She has completed two unsuccessful intrauterine insemination cycles and arrives at the clinic asking three questions: “Should we try IVF? What are my chances? And how should we plan if it doesn’t work?” For Mrs. K, prognosis counseling is the most consequential interaction with the clinic. Her age and ovarian reserve markers place her in a population where cumulative live birth probability (CLBP) estimates are miscalibrated against center-specific outcomes. A center-specific MLCS model trained on the clinic’s historical data ( 22 ) refines such estimates beyond national registry-based models. In the published MLCS validation, the model reclassified 23% of patients to CLBP ≥50% and 11% to CLBP ≥75%, correcting systematic prognosis underestimation—substantially more informative than population averages. These improvements translate directly to Mrs. K’s decision: whether to invest emotional and financial resources in three autologous attempts or consider donor oocytes earlier. This could be where AI delivers its highest-confidence near-term clinical value—software-only, EHR-integrated, and addressing prognosis miscalibration that affects every ARA patient. Mrs. K elects to proceed with two autologous cycles before reconsidering donor oocytes. For stimulation, the clinic uses an AI starting-dose model incorporating AMH, AFC, weight, age, and prior response when available. SHapley Additive exPlanations (SHAP) analysis of large IVF datasets identifies AFC and gonadotropin dosage among the top live birth predictors ( 100 ), and retrospective analyses of ML-guided dosing show reduced cycle cancellation and improved oocyte yield in low-prognosis patients ( 23 , 32 ). For Mrs. K, individualized dose calibration matters more than for a 32-year-old with normal reserve because conventional age-adjusted protocols systematically under- or over-respond in this population ( 44 ). Emerging dynamic mid-cycle adjustment models will further refine the stimulation trajectory based on real-time follicular response. Mrs. K’s first cycle yields three blastocysts. This is where the key ARA-AI amplification finding becomes operative. KIDScore AUC for live birth prediction rises from 0.596 at age <35 to 0.640 (35–37), 0.646 (38–40), 0.679 (41–42), and 0.768 at ≥43 ( 1 ). At Mrs. K’s age, the AI system’s discriminatory advantage over morphological assessment alone is at the upper end of its operative range, reflecting wider embryo-to-embryo quality variation from rising aneuploidy. The AI system can stratify implantation probability for the three blastocysts in a way morphological assessment cannot. While the 5–10 year horizon for T6 still applies to other subgroups, for ARA patients today, AI embryo assessment in time-lapse-equipped centers provides immediate adjunctive ranking value—CHLOE Blast or comparable platforms can provide explainable rankings communicated alongside conventional morphological grades. For Mrs. K, the aneuploidy rate among her blastocysts is expected to approach 70% at age 41, rising to >80% by age 43–45 ( 2 , 101 ). PGT-A is the current gold standard but is invasive and requires biopsy expertise. AI models predicting ploidy from static images achieve ~70% accuracy ( 77 ); however, PGT-A interpretation itself remains contested following evidence that mosaic blastocysts can yield viable ongoing pregnancies ( 102 ), introducing additional complexity that future non-invasive AI ploidy models will need to incorporate; the parallel extension of embryo screening to polygenic risk raises distinct scientific and ethical questions that remain unresolved ( 103 – 105 ). While AI cannot yet replace PGT-A as a definitive selector, it can prioritize which blastocysts to biopsy first or provide adjunctive ploidy information—the embryo assessment frontier where ARA patients could benefit most between now and 2031. Mrs. K’s first euploid blastocyst is transferred and yields a positive pregnancy test. Yet first-trimester miscarriage rises sharply with maternal age, exceeding 40% at ≥40 versus 10–15% at <35 in general-population data ( 81 ), driven by age-related oocyte aneuploidy ( 106 ). Even if AI-based preimplantation miscarriage risk scoring ( 31 ) could identify which frozen blastocysts carry higher risk, the current AUC of ~0.70 is not sufficient for advising against transfer. Should Mrs. K’s autologous cycles fail, the same MLCS model that informed her initial counseling can generate a revised CLBP estimate from her actual stimulation response, oocyte yield, fertilization rate, and embryo cohort quality. AI-assisted donor decision support, expected to mature in the 5–10 year horizon, will guide the autologous-versus-donor decision more precisely. Mrs. K’s case illustrates a typical ARA cascade: T1 frames the conversation, T2 maximizes biological yield, T6 selects optimally from limited embryos, and T8 will eventually inform implantation prognosis. Each technology delivers proportionally greater value in her case than in a younger patient with more forgiving ovarian reserve. Mrs. K’s journey illuminates why ARA patients could benefit most from AI integration. Technologies that deliver modest gains in younger patients could deliver disproportionately large gains here, driven by three converging amplifications: embryo quality variation widens with age, amplifying AI-based selection value (T6); individualized stimulation calibration matters more in diminished ovarian reserve (T2); and prognosis miscalibration carries higher impact when treatment windows are short (T1). The technology priority hierarchy for the ARA-focused 2026 clinic is therefore: T1 outcome prediction first, T2 stimulation dosing second, T6 embryo selection third (adjunctive in time-lapse-equipped centers), with T8 miscarriage risk prediction emerging as a Wave 3 priority. This exemplifies concentrated AI application to the IVF population for whom every decision matters.

In the last five years, artificial intelligence has moved from experimental curiosity to clinical deployment across radiology, pathology, ophthalmology, and cardiology. Reproductive medicine — and in vitro fertilization (IVF) in particular — occupies a distinctive position in this landscape. At every clinical stage, IVF generates multimodal data (i.e., demographics, hormonal profiles, ultrasound imaging, time-lapse embryo video, genetic testing, and cycle outcome records) that are captured in a closed-loop workflow with a measurable endpoint (live birth). This data architecture makes it one of the most AI-amenable disciplines in medicine ( 3 – 5 ). Since 1978, IVF has produced over twelve million births ( 6 , 7 ), yet only about one-third of cycles result in live birth ( 7 , 8 ). This establishes a clear performance ceiling that AI-augmented decision-making could help address. Importantly, the first FDA-cleared Machine Learning (ML) embryo assessment tool received 510(k) clearance in September 2025, and the first live birth from remotely controlled intracytoplasmic sperm injection (ICSI; operators separated by 3,700 km) was reported in 2025 ( 9 ). In addition, two completed multicenter RCTs of AI embryo selection have reported results. Key milestones that were achieved between approximately 2021 and 2026 are summarized in Supplementary Table 1 . Global AI adoption among IVF professionals rose from 24.8% in 2022 to 53.2% (any AI use across clinical domains) in 2025, with 83.62% of 2025 respondents indicating likely investment in AI within 1–5 years ( 10 ). However, these figures conceal a wide variance: different technologies are at vastly different readiness stages, with different evidence bases, different barriers to deployment, and different patient impacts. As such, the field is shifting from asking whether AI can improve outcomes toward asking which tools are ready for deployment, even as the former question remains incompletely answered for most technologies. The peer-reviewed literature primarily documents what AI can do under controlled conditions, but provides limited guidance on deployment sequence, resource requirements, or organizational prerequisites — creating decision paralysis for clinical leaders evaluating AI integration in IVF. Indeed, AI in IVF presents three counterintuitive realities that complicate implementation decisions. First, the technology with the highest commercial profile and research investment — AI embryo selection — is not the most ready for definitive deployment. The two large randomized trials have yielded divergent results. Second, the technology with a comparatively low profile — AI outcome prediction — could have the strongest near-term cost-avoidance case among the nine technologies considered (i.e., T1–T9). It requires no hardware capital and addresses prognosis miscalibration that affects every IVF patient. Third, the patient population most often dismissed as low-yield — patients aged ≥40 — is the population in whom AI’s discriminatory advantage is greatest. AI embryo selection demonstrates a steep, age-dependent increase in discriminatory accuracy, yielding its highest predictive value in patients over 40 ( 1 ). These three counterintuitive realities structure the analysis that follows. The review opens with a Methodology chapter establishing the analytical framework (four implementation frameworks, OCEBM evidence grading, NASSS sensitivity analysis, and conflict-of-interest protocol). It then presents the deployable 2026 AI toolkit early, before the full evidence appraisal, so that decision-makers can extract actionable guidance without first reading the technology-by-technology assessment. The Technology Assessment section organizes the nine technologies by their three-wave deployment readiness ( Supplementary Table 2 ), and a phase assignment of these technologies within the IVF clinical protocol is presented in Supplementary Table 3 as a secondary classification. The Patient Perspective section closes the technology-evidence block with the patient perspective on AI deployment. Subsequent chapters provide the evidence quality and critical appraisal (Evidence Quality and Critical Appraisal, encompassing study quality, research priorities, deployment-timeline confidence, and resource impact), failure modes (AI Failure Modes), implementation prerequisites (Implementation Prerequisites), procurement and integration considerations (Procurement), and an ARA-specific clinical synthesis built around a recurring patient case (The ARA Patient: Integrated Clinical Synthesis). Among the nine AI technologies, AI embryo selection (T6) has been identified as the primary anticipated benefit of AI in ART ( 10 ). However, four converging factors — divergent randomized controlled trial (RCT) results, platform-specific performance sensitivity, time-lapse hardware dependency, and the absence of a live-birth-endpoint regulatory clearance — have collectively placed AI embryo selection at the 5–10-year horizon, behind three immediately deployable software-only technologies (T1, T2, T3) as decision-support adjuncts. These results underscore that cautious optimism, rather than unconditional enthusiasm, is warranted. While the projected trajectory is optimistic, the evolutionary path of AI in the last five years — from concept to FDA clearance for embryo selection AI, from zero to robotic ICSI clinical deployment — beginning with 2 live births from the first automated ICSIA pilot ( 11 ), then the first fully remote ICSI live birth ( 9 ), then a Day 0 proof-of-concept multi-system series ( 12 ), and company-reported expansion to approximately 20 cumulative live births across all Conceivable systems by late 2025, from no RCTs to two completed multicenter trials — provides compelling empirical evidence that the software-based AI projections in this review are achievable within a 5-year horizon. While these projections apply broadly, their clinical impact is not uniformly distributed across patient populations. For patients of advanced reproductive age (ARA; ≥40 years), the readiness stratification carries direct clinical implications. The three software-only technologies in Wave 1 — AI outcome prediction (T1), stimulation dosing optimization (T2), and radio-frequency identification (RFID) quality tracking (T3) —are immediately applicable to ARA patients as decision-support adjuncts, where accurate prognosis and individualized dosing carry the greatest per-cycle value. Among the Wave 2 technologies, AI embryo selection (T6) demonstrates amplified discriminatory accuracy with advancing maternal age, making it the highest-priority medium-term investment for ARA-focused programs. Hardware-dependent technologies (T9) and those requiring multi-stream validation (T8) are projected beyond the 2031 horizon, but their eventual deployment will proportionally benefit older patients who carry the highest risk of failed implantation and early pregnancy loss.

Before these organizational prerequisites can be addressed, the evidence base itself requires critical scrutiny. This chapter provides a critical appraisal of the nine technologies along four complementary dimensions. The Evidence Quality Assessment subsection evaluates the strength of the underlying clinical evidence using an OCEBM-adapted hierarchy and a study-by-study quality assessment. The Research Priorities subsection translates the resulting evidence gaps into five concrete research priorities for the 2026–2031 agenda. The Deployment-Timeline Confidence subsection evaluates how confident the field can be in the projected deployment timelines. The Resource Impact Analysis subsection closes with a resource-impact analysis covering time, cost, training burden, and clinical-quality dimensions. Together they form the bridge between the technology evidence base and the implementation prerequisites that follow. Each technology was classified by an OCEBM-adapted hierarchy ( 90 ): Level 1 = multicenter RCT; Level 2 = single-center RCT or multicenter observational; Level 3 = retrospective cohort; Level 4 = case series or proof-of-concept; Level 5 = expert opinion or conference report only. Only AI embryo selection has achieved Level 1 evidence; most technologies remain at Level 2–3, while the sperm-related and robotic domains (T5b, T5c, T9) sit at Level 3–4 and rest predominantly on surrogate endpoints—classification accuracy, F1 score, or agreement with a reference method—rather than on clinical outcomes such as live birth. Within this hierarchy, Table 2 presents a quality assessment of the key clinical studies across five dimensions: study design, sample size, primary endpoint, key result, and risk of bias (RoB; encoded using Cochrane-style traffic light shading: + green = Low,? yellow = Moderate, − red = High). Supplementary Table 2 lists the full evidence-grading assignments. The two largest RCTs on AI embryo selection produced divergent results. The Illingworth et al. ( 27 ) trial used a time-lapse deep learning algorithm (iDAScore) across 14 clinics and found clinical pregnancy rate (CPR) of 46.5% versus 48.2% (risk difference −1.7%, 95% CI −7.7 to 4.3), failing non-inferiority. The LOTUS (Live birth Outcomes from Time-lapse Using AI) trial ( 28 , building on the AI-based viability prediction model originally developed by 91 ) used a static image-based AI system across 7 US clinics and found CPR of 72.9% versus 68.0%, meeting non-inferiority. The divergence likely reflects differences in AI architecture (video-based vs. static image), time-lapse hardware dependency, control group standardization, and patient population. This underscores that AI embryo selection is platform-dependent and cannot be treated as a uniform technology category. These platform-specific findings translate into clear clinical guidance: practitioners should evaluate specific AI embryo selection platforms against their patient demographics (ARA cohort vs general population), endpoint requirements (live birth vs implantation), and evidence depth (peer-reviewed vs conference-report) rather than treating ‘AI embryo selection’ as a uniform clinical category. Additional quality notes include: (1) Endometrial receptivity AI: the composite AUC 0.94 ( 30 ) carries high RoB for the reasons given in the T7 section; explainable-AI layers (e.g., saliency/attribution maps) are an additional prerequisite for deployment. (2) Miscarriage prediction: as documented in the T8 Miscarriage Prediction section, preimplantation AUC ~0.7 indicates modest discrimination; post-transfer ultrasound-based models achieve higher accuracy (AUC 0.97) but operate at a later timepoint ( 92 ). (3) Outcome prediction: the MLCS models ( 22 ) are retrospectively validated across 6 centers but have not yet been prospectively tested for their impact on patient decision-making or clinical outcomes; temporal data drift is a recognized concern. At least five research priorities have emerged from the tensions between current evidence and forward-looking projections of the 2031 IVF clinic. Each tension is paired with a concrete research action that, if undertaken systematically by ESHRE, ASRM, and national fertility societies, would resolve the tension and strengthen the evidence base supporting clinical adoption of these technologies. Priority 1 is a technology for which standards exist and require implementation; Priorities 2–5 are open scientific questions requiring new evidence generation. Our projection assumes AI embryo assessment will be standard by 2031. Current RCT evidence supports non-inferiority — not superiority — for one platform ( 28 ) and fails to support it for another ( 27 ). Non-randomized observational data from the single-center icONE pilot suggesting CPR of 77.3% ( 93 , conference abstract reporting preliminary results) cannot be extrapolated to RCT settings and should not inform projections. Research action: The projection is re-framed as “non-inferior with workflow efficiency benefits, pending platform-specific live birth endpoint validation” rather than “superior outcomes”. Clinics cannot extrapolate efficacy data across platforms. Cost is the top adoption barrier (38.01% of respondents, 2025) ( 10 ). While no peer-reviewed per-tool cost analysis exists as of April 2026, full-pipeline integration implies cumulative costs across multiple tools that have not been systematically modeled. Research action: Because cost-effectiveness data remain insufficient, formal incremental cost-effectiveness ratio (ICER) analysis per technology is a prerequisite for broad adoption (the Implementation Prerequisites section). 33.92% of professionals cite lack of training as a barrier ( 10 ), and the black-box nature of deep learning models limits trust ( 3 ). Research action: explainable AI (XAI) development and training curriculum reform are identified as prerequisites. As established in the T7 section, the AUC 0.94 evidence base is single-center and retrospective. The RNA-seq WOI prediction ( 94 ) requires invasive biopsy in a prior cycle, adding cost and time not justified outside the RIF population. Research action: Prospective multicenter validation with live birth endpoints is the field’s most urgent T7 research priority; until that evidence exists, T7 should be deployed only within supervised research protocols. The MLCS models ( 22 ) demonstrate significant inter-center variation in patient characteristics and live birth outcomes — precisely why center-specific models outperform national registry models. However, this means models require center-specific calibration and periodic revalidation as patient demographics and protocols change. Prospective impact studies assessing whether AI-guided counseling actually changes patient behavior and clinical outcomes are needed. Research action: Prospective impact studies — randomized evaluations of AI-guided versus standard counseling, with clinical outcomes as endpoints — are needed before T1 can claim to improve patient decision-making, not merely model performance. This section evaluates projected claims against general ML deployment experience. The evidence maturity and TRL positioning of all nine technologies is summarized in Figure 2 and assigns each technology to a confidence tier. Dual-axis assessment of nine AI technologies (T1–T9). (A) Evidence Maturity Dashboard: scatter plot positioning each technology by Technology Readiness Level (TRL 1–9, x-axis) against OCEBM evidence strength (y-axis; Level 1 = multicenter RCT at top, Level 5 = expert opinion at bottom). Three decision zones — Adopt Now (TRL ≥6.5 + OCEBM Level 1–2, green), Pilot/Investigate (moderate TRL or evidence, amber), and Wait & Watch (low TRL + weak evidence, red) — reflect readiness for clinical deployment. Bubble color encodes projected widespread deployment wave, not regulatory clearance status: blue = T1–T3 (≤5 yr, Adopt Now); amber = T4–T7 (5–10 yr, Pilot); red = T8–T9 (>10 yr, Future). T4 (Ultrasound) occupies TRL 7–8 owing to available FDA-cleared platforms but is coded amber because independent multicenter validation and broad deployment are projected at the 5–10 year horizon. T1 (Outcome Prediction) is positioned at TRL 7 consistent with multicenter prospective-validation cohort evidence (Level 2; 22 , 39 ). Exact TRL and OCEBM assignments for all nine technologies are provided in Supplementary Table 2 . (B) AI Maturity Map: quadrant plot positioning each technology by implementation readiness (x-axis, 1–10) against clinical impact potential (y-axis, 1–10). Dashed lines at x = 5 and y = 5 define four quadrants: Adopt Now (high readiness + high impact, upper right), High Impact/Low Readiness (upper left), High Readiness/Low Impact (lower right), and Reassess (lower left). T4 (AI ultrasound monitoring), T5b (AI sperm selection), and T7 (endometrial AI) carry unresolved generalizability limitations. T4’s 66% scan-time reduction is company-reported without independent replication. T5b evidence derives from a single center with surrogate endpoints. T7’s composite AUC derives from the single retrospective center described in the T7 section. Regulatory-cleared platforms (CHLOE Blast; Embryo Predict (Alife Health, CE marked)) can be deployed adjunctively in well-resourced centers within five years, but full deployment as the primary selection criterion requires the 5–10-year horizon pending resolution of the divergent RCT evidence detailed in the Evidence Quality Assessment subsection. The distinction is between T6 as an available adjunct (≤5 years) and T6 as a definitive replacement for morphology-based selection (5–10 years). T8 (miscarriage prediction as a transfer decision tool) and T9 (Robotic ICSI at scale) face barriers that preclude 2031 clinical deployment. T8’s AUC ~0.7 is insufficient for withholding transfer, and the ethical framework for doing so is absent. T9’s 4× speed limitation is a hardware engineering constraint requiring years of iteration beyond current capability. The full technology viability assessment across three adoption strata is summarized in Supplementary Table 2 . Overall, the first stratum (≤5 years) comprises software-only tools with Level 2–3 OCEBM evidence (T1: Level 2; T2: Level 3; T3: Level 2) and Simple–Complicated NASSS profiles — AI outcome prediction (T1), stimulation dosing (T2), and RFID quality tracking (T3). The second stratum (5–10 years) requires hardware augmentation, multicenter validation, and broader regulatory clearance — ultrasound monitoring (T4), sperm analysis and selection (T5), embryo selection beyond cleared platforms (T6), and endometrial receptivity AI (T7). The third stratum (>10 years), including autonomous miscarriage-based transfer decision support (T8) and robotic ICSI (T9), faces fundamental engineering constraints irrespective of algorithmic progress or unresolved ethical frameworks. The integration feasibility of these technologies heavily depends on three organizational prerequisites — EHR interoperability, LIMS application programming interface (API) access, and SaMD procurement capacity, instead of technology readiness alone. Centers investing in these prerequisites during 2026–2030 can deploy first-stratum tools within 12–18 months. The resource impact of each technology is rated across four dimensions: time savings, cost savings, training impact, and clinical quality/standardization ( Supplementary Table 6 ). Technologies with the highest immediate resource impact include: (1) AI Outcome Prediction/Counseling (T1) — no hardware required; if AI-guided counseling leads patients to forgo cycles with very low success probability, the theoretical cost avoidance could range from $12,000–$30,000 per avoided cycle in US ( 80 ), (2) RFID/Quality Tracking (T3) — mature technology delivering 25% laboratory cost reduction and zero-error sample traceability, (3) AI Endometrial Receptivity Assessment (T7) — avoidance of each failed FET represents $3–6K in direct cost avoidance ( 80 , 95 ). Future analyses should calculate the Incremental Cost-Effectiveness Ratio (ICER) per technology using Markov decision-tree models ( 80 ). On the other hand, in value-based or risk-sharing financing arrangements, time-to-pregnancy technologies (T6, T7) carry substantially higher economic value than in fee-for-service settings. Technologies with negative near-term resource impacts include Robotic systems (denudation, ICSI; T9) that currently increase procedure time and require substantial capital investment. Their resource benefit is realized only at scale with future speed improvements.

This review evaluated nine candidate AI technologies across the IVF clinical workflow. It organizes them into three deployment waves and envisions their implications for ARA patients. The principal finding is that readiness for clinical deployment is asymmetric with respect to development profile and clinical anticipation: Wave 1 software-only tools are deployable now with minimal capital, while several aspirational technologies remain hardware- or ethics-constrained beyond 2031. The potential age-dependent amplification of AI performance suggests ARA patients as the population for whom these tools yield the greatest incremental value. The three-wave adoption framework is the review’s principal contribution to clinical decision-making. Wave 1 technologies (T1–T3) share a defining characteristic absent from most AI-in-IVF discussions: they require no hardware capital expenditure — though EHR and LIMS integration carries substantial informatics labor costs. Wave 2 technologies (T4–T7) require multicenter prospective validation, and in most jurisdictions regulatory clearance. The divergent results from the iDAScore ( 27 ) and LOTUS ( 28 ) RCTs suggested that AI embryo selection is platform-specific, not a category-level technology. Efficacy data from one cleared platform cannot be extrapolated to another. Although the nine technologies were validated in IVF, the underlying clinical problems — ovarian response, gamete quality, embryo competence, endometrial receptivity, outcome prediction — are shared across reproductive medicine. T2 stimulation dosing could be applied directly to intrauterine insemination (IUI) and fertility preservation, and AI-supported elective single embryo transfer has been proposed as a further extension ( 107 ); T7 endometrial receptivity is relevant to frozen embryo transfer and recurrent pregnancy loss; T1 outcome prediction can be applied to improve oncofertility and social egg freezing. Furthermore, the ARA patient population emerges as the clearest priority for AI investment. The progressive increase in AI embryo selection AUC with maternal age ( 1 ) reflects that the wider embryo quality variation in older patients creates the discriminatory context in which AI pattern recognition outperforms human morphological assessment. This deviates from the conventional assumption that AI provides a uniform benefit. In this case, its value could be amplified the most in the population with the greatest clinical need. As detailed in the per-technology evaluation (T6 section), the ARA-amplification thesis advanced throughout this review rests on a single retrospective platform-specific analysis ( 1 ) and remains a hypothesis-generating observation pending prospective age-stratified multicenter validation. This limitation does not alter the deployment-readiness analysis but does mean that the designation of ARA patients as the primary AI-beneficiary population must be regarded as provisional until prospective validation data accrue. Beyond T1–T9, the 2031 horizon will be shaped by parallel developments such as AI-driven pharmacogenomics, oocyte cryopreservation outcome prediction, AI-microfluidic sperm selection, multi-omics integration ( 108 , 109 ), and generative adversarial network (GAN)-generated synthetic data ( 110 , 111 ) to overcome multicenter privacy constraints. Several analytical gaps limit this review: inherent selection bias as a narrative review; NASSS assessment not validated against empirical adoption data; several technologies (T5b and T7) are resting on single-center or company-reported data without independent replication, with T4 partially exempt (FOLLISCAN has peer-reviewed multicenter validation [ 25 ], though CycleClarity remains company-reported); and the cited evidence base draws predominantly from high-income settings (United States, European Union, United Kingdom, Japan, Australia), with limited primary data from low- and middle-income countries (LMICs), constraining generalizability to global IVF practice and to centers operating under different regulatory, reimbursement, and digital-infrastructure conditions. Important questions remaining for future research include, for example: whether live-birth-endpoint RCTs of AI embryo selection produce concordant results across platforms and populations; whether AI stimulation dosing translates the prospective evidence base into measurable reductions in ovarian hyperstimulation syndrome (OHSS) risk; whether the STAR system’s (microfluidic sperm recovery for non-obstructive azoospermia) first clinical pregnancy ( 68 ) can be replicated at scale in non-obstructive azoospermia cohorts; and whether AI miscarriage risk prediction reaches clinically actionable AUC levels (>0.80) after multi-stream data integration.

This review evaluates nine AI tools and asks which are ready for use today, which are still being tested, and which are still years away. We identify three tools ready for use in the next 12–18 months: software that helps doctors give patients more accurate estimates of their chance of having a baby through IVF, software that helps tailor the hormone dose for each patient during stimulation, and an electronic safety system that prevents mix-ups in the laboratory. None of these requires expensive new equipment. AI tools that help select the embryo most likely to lead to pregnancy show promise but have produced mixed results in two large clinical trials. So they should be treated as helpers — not replacements — for embryologist judgment. AI tools that predict miscarriage or that perform robotic injection of sperm into the egg are still in early research and not ready for routine use. For patients aged 40 and over, who face the greatest difficulties with IVF success, AI could offer proportionally greater benefit for identifying which embryos and which treatment plans are most likely to succeed. The review uses a recurring case — a 41-year-old patient with diminished ovarian reserve — to show how each AI tool would be used at each stage of her treatment journey. Importantly, four developments must occur between now and 2031 to make the AI-integrated IVF clinic a reality. They include clinical trials with live-birth outcomes, harmonized regulations across countries, ethical frameworks for AI-informed decisions, and training for doctors and embryologists/integration of AI with hospital electronic systems.

The 2031 AI-integrated IVF clinic, as projected by this analysis, is a stratified reality. First, Wave 1 AI tools require no hardware capital and can integrate within 12–18 months, making outcome prediction (T1), stimulation dosing (T2), and RFID quality tracking (T3) the immediate near-term priorities. Second, AI embryo selection (T6) is available adjunctively now in time-lapse-equipped centers and will serve as the primary selection criterion within the decade; however, divergent RCT results indicate that AI embryo assessment is platform-specific and cannot be adopted as a category. Center-specific validation is required. Third, Wave 2 endometrial receptivity (T7) is a high-priority Wave 2 research target requiring prospective multicenter validation, while Wave 3 miscarriage prediction (T8) and robotic ICSI (T9) require foundational ethical and engineering development beyond 2031 before they can become routine practice. Among the remaining Wave 2 technologies, AI ultrasound monitoring (T4) and sperm analysis and selection (T5) require independent multicenter validation before clinical adoption can be recommended. AI embryo selection is the highest-priority near-term target for ARA-focused programs, pending prospective age-stratified multicenter validation: KIDScore AUC has demonstrated steep age-dependent improvement ( 1 ) — meaning AI-based selection yields the greatest incremental value precisely where clinical need is the highest. Between now and 2031, four key tasks are rate-limiting: multicenter RCT completion with live birth endpoints, regulatory pathway harmonization, ethical frameworks for AI-informed transfer decisions, and workforce training and IT data infrastructure. Whether the AI-integrated IVF clinic fulfills its promise depends not on algorithmic sophistication but on the rigor with which the field validates, governs, and integrates these technologies into routine practice. Delays in any one of these key tasks will push the 2031 vision toward 2033–2035. For IVF clinic directors planning AI integration, the following implementation pathway emerges from this analysis. Months 1–6: deploy T1 (AI outcome prediction) for ARA patient counseling and donor-versus-autologous decision support; the software-only requirement and existing multicenter validation justify immediate adoption. Months 6–12: pilot T2 (AI stimulation dosing) in low-prognosis cohorts, with prospective tracking of MII oocyte yield as a primary metric; concurrently implement T3 (RFID quality tracking) as standard laboratory infrastructure. Year 2: evaluate T6 (AI embryo assessment) platforms specifically for ARA patients; for centers with time-lapse infrastructure, KIDScore’s AUC progression with maternal age (0.596 → 0.768) supports targeted adoption for this subpopulation. Year 3–5: pilot T4 (AI ultrasound monitoring; FOLLISCAN as the FDA-cleared peer-reviewed leader), T5 (sperm selection in research collaborations), and T7 (endometrial receptivity assessment) as capital infrastructure permits. Year 5+: monitor T8 (miscarriage risk prediction) for AUC improvements above the current ~0.70 threshold, and track T9 (robotic ICSI) for resolution of remote-procedure regulatory frameworks. This pathway reflects the central finding of this review: AI integration into IVF is not a single decision but a sequenced strategy, with immediate clinical value available in 2026 for clinics that prioritize software-first, evidence-validated deployment.

Beyond throughput, three engineering constraints separate a demonstrated live birth from a routine clinical service, and none is yet resolved. First, manipulation accuracy: ICSI requires the injection pipette to be positioned and driven through the oolemma within tolerances measured in micrometers, with penetration depth and needle trajectory controlled against an oocyte that is itself deformable and free to rotate. An automated system must therefore recover the pose of both pipette and oocyte in real time and must do so reliably enough that failure is detectable before damage occurs. Second, motion and path planning: the trajectory taken by the micropipette is not merely a matter of reaching the target, because the surrounding cytoplasm behaves viscoelastically and the path itself determines the mechanical load imposed. Path-planning methods that explicitly optimize the trajectory to minimize both path length and induced deformation have been formulated for viscoelastic micro-biological particles ( 86 ), but have not been validated in human oocytes. Third, cell deformation and gamete safety: deformation follows directly from the applied trajectory and force, and the tolerance of the human oocyte to prolonged mechanical loading during automated handling has not been characterized. Real-time control approaches developed toward ICSI automation illustrate both the feasibility of closed-loop manipulation and the difficulty of guaranteeing safety margins ( 87 ). However, critical limitations remain: automated ICSI averages 8.7 min/oocyte versus ~2 min manual, and post-denudation still requires embryologist intervention. Prolonged N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES)-buffer exposure during manipulation may also adversely affect embryo development ( 12 , 88 ). By 2031, robotic ICSI is expected in select high-volume centers, but full adoption requires further engineering iteration. The >10-year placement of T9 therefore follows from the conjunction of Level 4 evidence—proof-of-concept series without comparative trial—and these unresolved engineering constraints, rather than from the evidence grade alone.

This review applies a multi-framework approach combining Technology Readiness Level (TRL/MLTRL) scales, the IDEAL framework, Rogers’ Diffusion of Innovation theory, and the NASSS framework, with evidence graded using an OCEBM-adapted hierarchy. The nine candidate technologies (T1–T9) span the full IVF protocol and are analyzed for systematic AI benefit amplification in advanced reproductive age (ARA) patients. Coverage included PubMed/MEDLINE, Scopus, Google Scholar, and IEEE Xplore for English-language peer-reviewed articles, with a core search window of January 2021–March 2026 supplemented by foundational papers from January 2015 onward for technologies with pre-2021 origins (e.g., T3 RFID, T5 sperm-selection antecedents, T9 robotic ICSI), and by ASRM and ESHRE conference programs and FDA/EU MDR regulatory filings ( Supplementary Tables 1 , 4 [PRISMA-aligned]). Non-peer-reviewed sources were included only where they constituted the only available evidence and are classified at OCEBM Level 4–5 ( Supplementary Table 2 ). The frameworks are complementary in scope: TRL/MLTRL for technical maturity ( 13 – 15 ); IDEAL/IDEAL-D for procedural staging ( 16 , 17 ); Rogers for adoption trajectory ( 18 ); NASSS for organizational complexity ( 19 ); with DECIDE-AI informing early-stage clinical evaluation standards ( 20 ). TRL-level assignments were made by author judgment against the published rubrics for each framework, with full framework definitions, per-technology rationale, search strategy details, and NASSS sensitivity analysis methodology provided in the Supplementary Methods . Table 1 presents the NASSS domain complexity heatmap. RFID quality tracking is the only technology rated Simple overall; robotic ICSI and miscarriage prediction carry X (Complex) ratings in four or more domains. The Wider System domain rates Complicated or Complex for six of nine technologies, reflecting immature AI-specific regulatory frameworks ( 21 ). A structured sensitivity analysis re-examined each NASSS domain assignment against its supporting evidence: 55 of 63 ratings (87%) showed concordance with the underlying literature, and all discordant ratings, on adjudication, moved toward higher complexity ( Supplementary Methods , Section S.M.5). As a narrative review, selection bias is inherent; a systematic conflict-of-interest screening was integrated into evidence evaluation, with studies in Table 2 flagged for risk-of-bias when author–developer affiliations existed ( Supplementary Methods ). NASSS domain complexity assessment. Nine AI technologies rated across seven organizational domains using the NASSS framework ( 19 ). Cell shading encodes complexity: light blue, Simple (S); amber, Complicated (C); light red, Complex (X). Domain definitions: Condition, clinical context; Technology, algorithmic maturity; Value Prop., cost-effectiveness evidence; Adopter System, clinician acceptance; Organization, workflow integration; Wider System, regulatory environment; Embedding, long-term sustainability. Structured sensitivity analysis: 55/63 domain ratings (87%) showed concordance between the assigned complexity ratings and the supporting published evidence. Quality assessment of key clinical studies. Study design, sample size, primary endpoint, key result, and risk of bias (RoB; encoded using Cochrane-style traffic light shading: + green = Low,? yellow = Moderate, − red = High) for representative studies across each technology domain.

Many real-world AI deployments in healthcare systems fail at procurement. Company lock-in, ambiguous data ownership, undefined drift monitoring obligations, and unenforceable performance guarantees translate into operational risk that is invisible in technology readiness assessment. Software-based AI (T1, T2, T4, T5, T6, T7, T8) is typically structured as Software-as-a-Service (SaaS) operating expenditure — though T4 and T5 may additionally require proprietary imaging hardware with associated capital cost. Robotics (T9) could be delivered as a capital expenditure with multi-year depreciation, while RFID systems (T3) have hybrid arrangements. The appropriate contract architecture and total cost of ownership vary substantially by clinic volume, jurisdiction, payer system, and institutional procurement infrastructure. Three questions, however, are common to all institutional contracts. First — data ownership and portability: who owns the clinic’s data, the models trained on it, and what happens if the contract terminates or the company is acquired? Without explicit provisions, clinics commonly find that data fed to a company’s training pipeline cannot be retrieved or repurposed. Second — drift monitoring and update cadence: who is responsible for monitoring algorithmic drift over time, and who validates updates before they reach clinical workflow? ( 78 ). Third — uptime, performance, and remediation: what service-level agreement governs uptime, what performance benchmarks must the model maintain, and what compensation is owed for downtime or performance degradation? Beyond these three, procurement decisions are mostly institution-specific and require dedicated finance, legal, and informatics input that lies outside the scope of this review.

Beyond the failure modes addressed in the preceding chapter, realization of the 2031 vision could require progress across four prerequisite clusters that span evidence generation, regulatory pathways, ethics, and workforce and data infrastructure. Procurement considerations, addressed briefly in the section that follows, constitute the operational layer that determines whether AI deployment actually delivers clinical value. To realize the 2031 vision, at least 5–10 multicenter RCTs covering diverse platforms, populations, and geographies with live birth as primary endpoint are needed ( 71 ). The ‘Croatia Consensus’ (a proposed international validation framework; 63 for AI in embryo assessment) validation framework needs to be endorsed by ESHRE and ASRM within five years ( 30 ). For miscarriage prediction, the ethical framework for withholding transfer must be developed in parallel with technical validation. Regulatory classification of AI-based IVF tools varies substantially across the six jurisdictions assessed in Table 5 (FDA, EU MDR, UK HFEA, Australia TGA, Japan PMDA, China NMPA) ( 97 ). A fundamental divergence — between the FDA’s Predetermined Change Control Plan (PCCP), which permits continuously-learning algorithm updates without resubmission, and the EU AI Act, which requires conformity reassessment for material modifications — creates a higher barrier to adaptive AI in Europe ( 21 , 69 ). Cross-border data-flow compliance and robotic-system safety certification pathways remain underdeveloped across all jurisdictions, and national IVF data-sharing frameworks analogous to SART or HFEA are absent outside the US and UK, limiting population-specific validation. Regulatory classification of AI-based IVF tools across six jurisdictions. Regulatory body, AI classification pathway, clearance status as of April 2026, and key jurisdictional notes for each of the six regulatory frameworks assessed: FDA (United States), EU MDR (European Union), HFEA (United Kingdom), TGA (Australia), PMDA (Japan), and NMPA (China). Clear frameworks are needed for algorithmic transparency, informed consent for AI-assisted embryo selection, and data privacy in AI-integrated workflows in most countries ( 98 , 99 ). The ethical dimensions of AI in family creation require ongoing public engagement, and professional society position statements would provide the starting points for these issues ( 70 ). AI competency, including data science literacy, appropriate use of AI tools, and robotic system supervision, must be integrated into reproductive medicine training for clinicians and embryologists ( 45 , 78 ). Embryologists’ roles will transition from manual operators to quality control supervisors and system optimization experts, and this requires entirely new training curricula. The multi-modal embryo assessment cannot be realized without a system that unifies imaging, EHR, and genetic testing data standards ( 3 , 38 ). Because deployment timelines are frequently determined by IT infrastructure (e.g., EHR/LIMS integration, cybersecurity audits, and informatics labor), rather than AI readiness, a lack in this aspect could extend timelines by 1–2 years, representing a hidden cost absent from most implementation cost estimates ( 78 ). In addition, manual fallback protocols and continuous AI proficiency assessments must be established to ensure efficient operation ( 38 ).

Of the nine AI technologies evaluated, three Tier 1 software-only applications offer immediate clinical implementation value with minimal capital investment. T1 (AI outcome prediction): the Yao et al. ( 22 ) multicenter MLCS validation across six US fertility centers (N = 4,635 first IVF cycles) demonstrates PR-AUC 0.75 versus the SART model’s 0.69 (p<0.05), with 23% of patients reclassified to live birth probability ≥50% and 11% to ≥75% — directly translating to higher-fidelity ARA counseling and donor-versus-autologous decision support. T2 (stimulation dosing): Fanton et al. ( 23 ) multicenter retrospective evidence (3 US ART centers, N = 18,591 cycles) identifies per-patient dose–response curves that improve MII oocyte yield in low-prognosis patients, with an interpretable starting-dose model that facilitates clinician trust. T3 (RFID quality tracking): established sample chain-of-custody and witnessing technology, deployable in any IVF laboratory within standard quality assurance budgets. Two Tier 2 applications additionally offer immediate adjunctive value where infrastructure permits: T4 (AI ultrasound monitoring) via FOLLISCAN ( 25 ; peer-reviewed multicenter validation across N = 1,689 cycles) provides radiation-free, AI-assisted ovarian monitoring with validated precision and F1 metrics; and T6 (AI embryo assessment) for ARA patients, where Kato et al. ( 1 ) demonstrates AUC progression from 0.596 (age <35) to 0.768 (age ≥43) — a 29% relative gain in discriminatory power precisely in the population where embryo selection decisions carry the highest clinical stakes.